Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)

Next Previous
Search
Trial Profile

Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Cerebral ischaemia; Subarachnoid haemorrhage
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prolong Pharmaceuticals

    • Most Recent Events

    • 24 Feb 2017 Results presented at the 42nd International Stroke Conference.
    • 26 Oct 2016 Status changed from recruiting to completed.
    • 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top